These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

626 related items for PubMed ID: 19201878

  • 1. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection.
    Phalipon A, Tanguy M, Grandjean C, Guerreiro C, Bélot F, Cohen D, Sansonetti PJ, Mulard LA.
    J Immunol; 2009 Feb 15; 182(4):2241-7. PubMed ID: 19201878
    [Abstract] [Full Text] [Related]

  • 2. Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine.
    Phalipon A, Costachel C, Grandjean C, Thuizat A, Guerreiro C, Tanguy M, Nato F, Vulliez-Le Normand B, Bélot F, Wright K, Marcel-Peyre V, Sansonetti PJ, Mulard LA.
    J Immunol; 2006 Feb 01; 176(3):1686-94. PubMed ID: 16424198
    [Abstract] [Full Text] [Related]

  • 3. Rational design and immunogenicity of liposome-based diepitope constructs: application to synthetic oligosaccharides mimicking the Shigella flexneri 2a O-antigen.
    Said Hassane F, Phalipon A, Tanguy M, Guerreiro C, Bélot F, Frisch B, Mulard LA, Schuber F.
    Vaccine; 2009 Aug 27; 27(39):5419-26. PubMed ID: 19559116
    [Abstract] [Full Text] [Related]

  • 4. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
    Cohen D, Atsmon J, Artaud C, Meron-Sudai S, Gougeon ML, Bialik A, Goren S, Asato V, Ariel-Cohen O, Reizis A, Dorman A, Hoitink CWG, Westdijk J, Ashkenazi S, Sansonetti P, Mulard LA, Phalipon A.
    Lancet Infect Dis; 2021 Apr 27; 21(4):546-558. PubMed ID: 33186516
    [Abstract] [Full Text] [Related]

  • 5. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
    Passwell JH, Ashkenazi S, Harlev E, Miron D, Ramon R, Farzam N, Lerner-Geva L, Levi Y, Chu C, Shiloach J, Robbins JB, Schneerson R, Israel Shigella Study Group.
    Pediatr Infect Dis J; 2003 Aug 27; 22(8):701-6. PubMed ID: 12913770
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Construction of a multivalent vaccine strain of Shigella flexneri and evaluation of serotype-specific immunity.
    Jennison AV, Roberts F, Verma NK.
    FEMS Immunol Med Microbiol; 2006 Apr 27; 46(3):444-51. PubMed ID: 16553820
    [Abstract] [Full Text] [Related]

  • 8. Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge.
    Kelly M, Janardhanan J, Wagh C, Verma S, Charles RC, Leung DT, Kamruzzaman M, Pansuriya RK, Chowdhury F, Vann WF, Kaminski RW, Khan AI, Bhuiyan TR, Qadri F, Kováč P, Xu P, Ryan ET.
    Vaccine; 2024 Oct 24; 42(24):126263. PubMed ID: 39217775
    [Abstract] [Full Text] [Related]

  • 9. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.
    Ashkenazi S, Passwell JH, Harlev E, Miron D, Dagan R, Farzan N, Ramon R, Majadly F, Bryla DA, Karpas AB, Robbins JB, Schneerson R.
    J Infect Dis; 1999 Jun 24; 179(6):1565-8. PubMed ID: 10228084
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Development of Shigella conjugate vaccines targeting Shigella flexneri 2a and S. flexneri 3a using a simple platform-approach conjugation by squaric acid chemistry.
    Kelly M, Mandlik A, Charles RC, Verma S, Calderwood SB, Leung DT, Biswas R, Islam K, Kamruzzaman M, Chowdhury F, Khanam F, Vann WF, Khan AI, Bhuiyan TR, Qadri F, Vortherms AR, Kaminski R, Kováč P, Xu P, Ryan ET.
    Vaccine; 2023 Jul 31; 41(34):4967-4977. PubMed ID: 37400283
    [Abstract] [Full Text] [Related]

  • 18. Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice.
    Farzam N, Ramon-Saraf R, Banet-Levi Y, Lerner-Geva L, Ashkenazi S, Kubler-Kielb J, Vinogradov E, Robbins JB, Schneerson R.
    Vaccine; 2017 Sep 05; 35(37):4990-4996. PubMed ID: 28797729
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Live attenuated Salmonella Typhimurium with monophosphoryl lipid A retains ability to induce T-cell and humoral immune responses against heterologous polysaccharide of Shigella flexneri 2a.
    Liu Q, Su H, Bian X, Wang S, Kong Q.
    Int J Med Microbiol; 2020 Jul 05; 310(5):151427. PubMed ID: 32654768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.